Mersana Therapeutics Inc (MRSN) — Cash Flow-to-Debt Ratio
Mersana Therapeutics Inc (MRSN) has a Cash Flow-to-Debt Ratio of -0.03x as of September 2025, meaning its operating cash flow of $-3.19 Million could theoretically repay 0% of its total liabilities ($122.22 Million) in one year. Explore MRSN strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Mersana Therapeutics Inc Cash Flow-to-Debt Ratio (2015–2024)
Historical debt coverage capacity for Mersana Therapeutics Inc across 10 annual periods. Also explore Mersana Therapeutics Inc assets under control for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Mersana Therapeutics Inc (2015–2024)
Year-by-year debt coverage analysis for Mersana Therapeutics Inc. For market capitalisation and broader financial context, see Mersana Therapeutics Inc market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.53x | $-82.34 Million | $154.17 Million | ▲ +40.2% |
| 2023 | -0.89x | $-168.88 Million | $189.16 Million | ▼ -338.2% |
| 2022 | -0.20x | $-49.36 Million | $242.28 Million | ▲ +87.7% |
| 2021 | -1.66x | $-139.99 Million | $84.37 Million | ▼ -0.7% |
| 2020 | -1.65x | $-74.70 Million | $45.31 Million | ▲ +28.9% |
| 2019 | -2.32x | $-67.74 Million | $29.22 Million | ▼ -192.7% |
| 2018 | -0.79x | $-55.22 Million | $69.71 Million | ▼ -12.7% |
| 2017 | -0.70x | $-42.68 Million | $60.72 Million | ▼ -457.6% |
| 2016 | 0.20x | $31.59 Million | $160.71 Million | ▲ +216.5% |
| 2015 | -0.17x | $-9.64 Million | $57.10 Million | — |